Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2.

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2.
复制标题

DOI:
10.1016/j.celrep.2021.108959
复制
发表时间:
2021-04-06
期刊:
影响因子:
8.8
通讯作者:
Cherry S
Cherry S
中科院分区:
生物学1区
文献类型:
--
作者:
Dittmar M;Lee JS;Whig K;Segrist E;Li M;Kamalia B;Castellana L;Ayyanathan K;Cardenas-Diaz FL;Morrisey EE;Truitt R;Yang W;Jurado K;Samby K;Ramage H;Schultz DC;Cherry S

文献摘要

参考文献

被引文献

相似文献

目前迫切需要抗病毒药物来治疗新出现的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)。为了确定新的候选药物,我们筛选了一个重新调整用途的∼3,000药物库。在Vero细胞中筛选发现的抗病毒药物很少,而在人类Huh7.5细胞中筛选验证了23种不同的抗病毒药物。将我们的研究延伸到肺上皮细胞,我们发现这些细胞对SARS-CoV-2的药物敏感性和进入途径有很大的差异。进入肺上皮细胞Calu-3不依赖于pH,需要TMPRSS2,而进入Vero和Huh7.5细胞需要低pH,并由酸性依赖内体蛋白酶触发。此外,我们发现9种药物是呼吸道细胞中的抗病毒药物,其中7种已用于人类,3种是美国食品和药物管理局(FDA)批准的,包括环孢素。我们发现环孢素的抗病毒活性是针对亲环素而不是钙调神经磷酸酶,揭示了具有快速临床应用潜力的基本宿主靶点。迫切需要抗病毒药物来治疗新出现的SARS-CoV-2。Dittmar等人。发现九种宿主导向的药物在呼吸道细胞中是抗病毒的,其中七种已经用于人类,三种是FDA批准的。我们展示了具有快速临床实施潜力的宿主目标。
There is an urgent need for antivirals to treat the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To identify new candidates, we screen a repurposing library of ∼3,000 drugs. Screening in Vero cells finds few antivirals, while screening in human Huh7.5 cells validates 23 diverse antiviral drugs. Extending our studies to lung epithelial cells, we find that there are major differences in drug sensitivity and entry pathways used by SARS-CoV-2 in these cells. Entry in lung epithelial Calu-3 cells is pH independent and requires TMPRSS2, while entry in Vero and Huh7.5 cells requires low pH and triggering by acid-dependent endosomal proteases. Moreover, we find nine drugs are antiviral in respiratory cells, seven of which have been used in humans, and three are US Food and Drug Administration (FDA) approved, including cyclosporine. We find that the antiviral activity of cyclosporine is targeting Cyclophilin rather than calcineurin, revealing essential host targets that have the potential for rapid clinical implementation. There is an urgent need for antivirals to treat the newly emerged SARS-CoV-2. Dittmar et al. find nine host-directed drugs are antiviral in respiratory cells, seven of which have been given to humans, and three are FDA approved. We show host targets that have the potential for rapid clinical implementation.
DOI: 10.1038/nrmicro.2016.81
发表时间: 2016-08
期刊: Nature reviews. Microbiology
影响因子: --
作者:
de Wit E;van Doremalen N;Falzarano D;Munster VJ
通讯作者: Munster VJ
DOI: 10.1056/nejmoa2016638
发表时间: 2020-08-06
影响因子: 158.5
作者:
Boulware, David R.;Pullen, Matthew F.;Hullsiek, Kathy H.
通讯作者: Hullsiek, Kathy H.
DOI: 10.1128/jvi.02232-10
发表时间: 2011-05-01
影响因子: 5.4
作者:
Glowacka, Ilona;Bertram, Stephanie;Poehlmann, Stefan
通讯作者: Poehlmann, Stefan
DOI: 10.1099/vir.0.034983-0
发表时间: 2011-11-01
影响因子: 3.8
作者:
de Wilde, Adriaan H.;Zevenhoven-Dobbe, Jessika C.;van Hemert, Martijn J.
通讯作者: van Hemert, Martijn J.
DOI: 10.1099/vir.0.052910-0
发表时间: 2013-08
期刊: The Journal of general virology
影响因子: --
作者:
de Wilde AH;Raj VS;Oudshoorn D;Bestebroer TM;van Nieuwkoop S;Limpens RWAL;Posthuma CC;van der Meer Y;Bárcena M;Haagmans BL;Snijder EJ;van den Hoogen BG
通讯作者: van den Hoogen BG